GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts
As of December 3, 2025, GSK plc (LSE:GSK, NYSE:GSK) is trading near multi‑year highs after a year of earnings beats, a revived oncology franchise, heavy share buybacks and an unusually busy FDA calendar for December. At the same time, analysts are still only lukewarm on the stock, and long‑term growth expectations lag management’s ambitions. This is a deep dive into where GSK stock stands today, what’s driving the rally, and what current news and forecasts are signalling about 2026 and beyond. GSK share price today and 2025 performance On the NYSE, GSK’s U.S. ADR is trading around $48.27 in early